Back to top
more

Ionis Pharmaceuticals (IONS)

(Delayed Data from NSDQ)

$51.45 USD

51.45
766,354

-0.41 (-0.79%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $51.42 -0.03 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (97 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ionis (IONS) Posts Wider than Expected Loss in Q2, Sales Miss

by Zacks Equity Research

Ionis posts wider than expected loss and sales miss estimates in the second quarter of 2018.

    Is a Beat in Store for Ionis (IONS) This Earnings Season?

    by Zacks Equity Research

    On Ionis' (IONS) second-quarter 2018 conference call, investor focus will remain on the company's progress with the pipeline candidates as well as royalty revenues earned from Spinraza.

      Biogen (BIIB) Q2 Earnings & Sales Beat Estimates, Shares Up

      by Zacks Equity Research

      Biogen (BIIB) beats estimates on both counts in the second quarter. The company's multiple sclerosis drugs' sales up sequentially amid competition.

        Biotech Stock Roundup: AMGN Resubmits Evenity BLA, Advaxis Soars, Regulatory Updates

        by Zacks Equity Research

        It has been a pretty ho-hum week for the biotech sector with a few regulatory updates. Amgen resubmits BLA for osteoporosis drug and Advaxis surges on positive news from FDA.

          Bristol-Myers' Combo Drugs Get FDA Nod for Colorectal Cancer

          by Zacks Equity Research

          Bristol-Myers' (BMY) Opdivo in combination with its Yervoy received the FDA approval to treat patients with metastatic colorectal cancer (mCRC) that has progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan.

            Summit Therapeutics (SMMT) Catches Eye: Stock Jumps 8.8%

            by Zacks Equity Research

            Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

              Regulus Stock Plunges on Cash Concerns Despite Restructuring

              by Zacks Equity Research

              Regulus Therapeutics (RGLS) announces strategic and restructuring plans to extend cash runway. However, investors remain skeptical.

                Pfizer's Tafamadis Gets Breakthrough Therapy Designation

                by Zacks Equity Research

                Pfizer's (PFE) rare disease candidate, tafamidis, gets Breakthrough Therapy designation in the United States for the treatment of transthyretin cardiomyopathy.

                  Ionis (IONS) Beats Earnings & Misses Revenues in Q1

                  by Zacks Equity Research

                  Ionis Pharmaceutical (IONS) reported positive quarter with earnings beating estimates while revenues missing the same.

                    What's in the Cards for Ionis (IONS) This Earnings Season?

                    by Zacks Equity Research

                    Ionis Pharmaceuticals (IONS) earns $30 million in license payments from AstraZeneca. Spinraza witnesses strong first quarter as announced by Biogen in its earnings release.

                      Ionis Pharmaceuticals (IONS) in Focus: Stock Moves 5.8% Higher

                      by Zacks Equity Research

                      Shares of Ionis Pharmaceuticals (IONS) rose 5.8% on Friday.

                        Ionis (IONS) Clinches Licensing Agreement with AstraZeneca

                        by Zacks Equity Research

                        Ionis (IONS) inks a licensing deal with AstraZeneca per which the former will license IONIS-AZ6-2.5-LRx to AstraZeneca for the treatment of NASH.

                          Alnylam Falls on Pfizer's Rare Disease Drug Success

                          by Zacks Equity Research

                          Shares of Alnylam (ALNY) fall by more than 8% after Pfizer reports top-line results from the phase III study of tafamidis.

                            Pfizer's Rare Disease Candidate Meets Endpoint in Phase III

                            by Zacks Equity Research

                            Pfizer's (PFE) pipeline candidate tafamidis, developed for the treatment of transthyretin cardiomyopathy (TTR-CM), meets the main goal in a late-stage study.

                              Biogen to Buy Mid-Stage Neuropsychiatry Asset From Pfizer

                              by Zacks Equity Research

                              Biogen (BIIB) agrees to pay $75 million upfront to buy mid-stage candidate from Pfizer, which is being developed for cognitive impairment associated with schizophrenia (CIAS).

                                Ionis (IONS) Beats Both Earnings & Revenues in Q4

                                by Zacks Equity Research

                                Ionis Pharmaceutical (IONS) reported positive quarter with earnings and revenues beating estimates.

                                  What's in the Cards for Ionis (IONS) This Earnings Season?

                                  by Zacks Equity Research

                                  Ionis Pharmaceuticals (IONS) earns $70 million in milestone and license payments from several drug companies. Spinraza witnesses strong fourth quarter as announced by Biogen in its earnings release.

                                    Ionis Out-Licenses Second Candidate to AstraZeneca, Earns $30M

                                    by Zacks Equity Research

                                    Ionis Pharmaceuticals (IONS) out-licenses Generation 2.5 antisense drug to AstraZeneca under a strategic collaboration agreement.

                                      Biogen Halts Tysabri Development in Stroke as Study Fails

                                      by Zacks Equity Research

                                      Biogen's Tysabri (natalizumab) falters in a phase IIb study, evaluating it for acute ischemic stroke (AIS) indication.

                                        Implied Volatility Surging for Ionis Pharmaceuticals (IONS) Stock Options

                                        by Zacks Equity Research

                                        Surging implied volatility makes Ionis Pharmaceuticals (IONS) stock lucrative to the option traders.

                                          Biogen, Ionis Ink Deal for Spinal Muscular Atrophy Therapies

                                          by Zacks Equity Research

                                          Biogen (BIIB) expands collaboration with Ionis to identify new drug candidates for the treatment of SMA.

                                            Indrajit Bandyopadhyay headshot

                                            Ionis (IONS) Beats on Q3 Earnings, Revenues Miss

                                            by Indrajit Bandyopadhyay

                                            Ionis Pharmaceutical (IONS) reported mixed quarter with earnings beating estimates while revenues missing it.

                                              Should You Buy Ionis (IONS) Ahead of Earnings?

                                              by Zacks Equity Research

                                              Ionis Pharmaceuticals, Inc. (IONS) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

                                                Is a Beat in Store for Ionis (IONS) This Earnings Season?

                                                by Zacks Equity Research

                                                Ionis Pharmaceuticals (IONS) earned $50 million in milestone payments from Biogen. Spinraza had a strong third quarter as announced by Biogen in its earnings results.

                                                  4 Scorching Hot Momentum Stocks to Beat the Market

                                                  by Zacks Equity Research

                                                  This screen will help you to get into momentum stocks that are storming ahead. Highlighted stocks include: IONS, OSB and SKX.